Stem Cell Technology Center Genetica

Certificate of Analysis 2020

Invoice number: SCTC2019-00064

Name investigator: Anneke den Hollander
Cell line number: IPS19-00053 clone 1
Project name: VICI

Table 1: Information on the reprogrammed cell line

Information cell line:	
Product description	PBMCs nucleofected with episomal vectors containing the genes OCT3/4, SOX2, KLF4, L-MYC, LIN28
Parental cell line	HEP18-00176
Parental cell type	PBMCs
Diagnosis	MD-BLD
Mutation	N/A*
Number of clones	1
Passage (P) of iPSCs reported at submission	P10
Culture medium	Essential 8 Flex medium
Culture coating	Matrigel
Feeders during reprogramming	Mouse Embryonic Fibroblasts (MEFs)
Passage method	0.5 mM EDTA
Protocols in Q-portal	046588; 046591

Table 2: Information on the characterization of the reprogrammed cell line

Test description:	**Test method:**	**Test specification:**	**Result:**
Activation of stem cell markers	qPCR	Upregulation of *SOX2, LIN28, NANOG, DNMT3B* compared with PBMCs	Pass
Expression of stem cell markers	Immunocytochemistry	Expression of OCT4, NANOG, SSEA4, TRA-1-81	Pass
Mycoplasma	PCR	Negative	Pass
Three lineage differentiation	Differentiation assay	Upregulation of germlayer-specific genes	Pass
Copynumbervariation (CNV) analysis	Array	Comparing the genetic profile with the donor DNA	Pass



Figure 1: Cells prior to freezing.

Activation of stem cell markers

The iPSC clone was assessed for activation of stem cell markers before freezing. RNA was isolated and gene expression was assessed by quantitative reverse transcription PCR. Ct values were normalized with the housekeeping gene GUSB (set at 1).



Figure 2: Gene expression of the iPSC clone compared with the parental PBMCs (ΔCt).



Figure 3: Pluripotency gene upregulation after reprogramming (ΔΔCt). The expression fold difference of the iPSC clone is relative to the parental PBMCs.

Expression of stem cell markers

The undifferentiated iPSC clone was stained for the nuclear markers NANOG and OCT4 and surface antigens SSEA4 and TRA-1-81. All markers are expressed in human pluripotent stem cells.

A. IPS19-00053 clone 1



Figure 4: Immunofluorescence staining of the iPSC clone with pluripotency markers.

Three germ layer differentiation

IPS19-00053 clone 1 was differentiated into the endodermal, mesodermal and ectodermal germ layers. RNA was isolated and gene expression was checked by qPCR. Ct values are normalized with the housekeeping gene GUSB (set at 1). For each lineage two genes were assessed (Table 3). The differentiated cells were also stained for lineage-specific markers (Table 4).

Table 3: qPCR markers for three lineage differentiation

Lineage	Marker
Endoderm	FOXA2, SOX17
Mesoderm	Brachyury, HAND1
Ectoderm	PAX6, NCAM1

Table 4: ICC markers for three lineage differentiation

Lineage	Marker
Endoderm	SOX17
Mesoderm	NCAM1
Ectoderm	NESTIN

Endoderm



Figure 5: Expression fold difference of endoderm-specific genes in differentiated cells, compared with the undifferentiated iPSC clone. *SOX2* was used as a reference for pluripotency.

Mesoderm



Figure 6: Expression fold difference of mesoderm-specific genes in differentiated cells, compared with the undifferentiated iPSC clone. *SOX2* was used as a reference for pluripotency.

Ectoderm



Figure 7: Expression fold difference of ectoderm-specific genes in differentiated cells, compared with the undifferentiated iPSC clone. *DNMT3B* was used as a reference for pluripotency.



Figure 8: Immunofluorescence staining of differentiated cells showing positive signal of germlayer-specific markers.

CNV analysis

The DNA was isolated from the iPSC clone (IPS19-00053) and the donor's blood (HEP19-00035) before performing the CNV analysis, to determine abnormalities caused by reprogramming and passaging of the iPSC clone.

Table 5: The CNVs found in the iPSC clone DNA and the donor DNA

IPS19-00053	HEP19-00035
chr2: 6,528,496 - 6,541,600	chr3: 57,994,310 - 58,071,249
chr2: 142,085,282 - 142,101,651	chr4: 186,396,026 - 186,421,554
chr2: 178,707,959 - 178,718,259	chr9: 740,711 - 747,279
chr3: 57,997,191 - 58,068,993	chr10: 83,321,049 - 83,335,187
chr4: 5,165,112 - 5,181,354	chrX: 5,485,219 - 5,496,137
chr4: 13,946,439 - 13,963,189	chrX: 2,668,660 - 155,233,732
chr4: 93,359,483 - 93,413,386	chrY: 2,650,141 - 28,799,938
chr4: 185,728,251 - 185,745,179	
chr5: 13,300,717 - 13,310,832	
chr6: 161,032,089 - 161,047,367	
chr7: 46,248,354 - 46,263,100	
chr7: 122,016,870 - 122,096,743	
chr8: 36,882,518 - 36,898,253	
chr8: 58,057,656 - 58,085,637	
chr8: 137,529,500 - 137,547,267	
chr9: 740,711 - 747,279	
chr9: 2,011,339 - 2,018,826	
chr10: 71,215,029 - 71,226,467	
chr10: 83,321,049 - 83,340,133	
chr14: 22,586,012 - 22,624,121	
chr14: 22,697,047 - 22,804,705	
chr14: 22,879,738 - 22,937,657	
chr14: 88,402,596 - 88,414,876	
chr15: 46,850,449 - 46,861,458	
chr15: 101,023,554 - 101,038,781	
chr17: 32,616,389 - 32,632,239	
chr20: 51,655,327 - 51,672,079	
chr22: 45,199,434 - 45,209,773	
chrX: 5,485,209 - 5,496,137	
chr8: 133,808,933 - 140,565,684	
chrX: 2,693,476 - 155,233,732	
chrY: 2,650,141 - 28,799,938	

Conclusion:

All of the differences shown in the iPSC collumn in table 5 are due to noise.

- (●) Pass
- ( ) Fail
- ( ) Other:

Silvia Albert

Silvia Albert, PhD
Manager, Radboud Stem Cell Technology Center
Date 11.11.2020